IL6 and chronic obstructive pulmonary disease: Such aberrant liver metabolism may not be limited to the context of cancer: the hepatic effect of IL-6 in tumor-free mice is dose dependent across the range observed in tumor-bearing mice (Figures 3A, 3C, and 3D), implicating the process in a wide range of IL-6-associated diseases where weight loss is observed, such as sepsis, HIV, tuberculosis, chronic obstructive pulmonary disease, cardiac failure, and rheumatoid arthritis.